Compare Altria Group Inc (MO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Altria Group Inc trades at $73.25 (market cap $124.67B), while Vertex Pharmaceuticals Incorporated trades at $480.98 (market cap $121.95B). The key difference: Altria Group Inc and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Altria Group Inc pays a 5.68% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MO | VRTX | |
|---|---|---|
Market Cap | $124.67B | $121.95B |
Sector | Consumer Staples | Health |
52-Week High | $74.66 | $529.59 |
52-Week Low | $54.72 | $366.54 |
Enterprise Value | $145.75B | $116.69B |
Dividend Yield | 5.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
